Emergent BioSolutions, Inc. (NYSE:EBS) announced its financial results for the first quarter ended March 31, 2011. For 1Q 2011, total revenues were $18.5 million as compared to $46.8 million in 2010. In addition, for 1Q 2011 the company recorded a net loss of $21.4 million, or $0.61 per basic share, as compared to net income of $2.5 million, or $0.08 per basic share, in 2010. R. Don Elsey, chief financial officer of Emergent BioSolutions, stated, "While our first quarter revenues were slightly lower than expected, we remain on track to achieve our full year guidance of total revenues of $320 to $340 million and net income of $35 to $45 million."
Emergent BioSolutions Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and antibody therapeutics primarily in the United States, the United Kingdom, and Vietnam. The company operates in two segments, BioDefense and BioSciences.
Global Hunter Corp. (BOB.V)
Metals are often found as compounds in ores. An ore is a rock or mineral that has enough metal in it to make it worth extracting. In the case of copper, it is worth extracting when there is about 2 kg of copper per 1000 kg of ore.
About 200 years ago the UK was an important world source of copper and there were mines in Cornwall and Wales. These mines have now closed and today the biggest copper mines are in Chile and North America. These produce many thousands of tonnes of copper ore per year. The main ores of copper are; chalcopyrite, bornite, malachite.
The ores are extracted by either traditional mining (open pit or underground) or by leaching. The copper is then recovered using physical and chemical techniques. There are many types of copper ore found throughout the world. About 80% of all copper extracted comes from sulphide ores. A typical ore contains only 0.5% to 2.0% copper. It is a measure of the value of copper that it is worth extracting it from such small concentrations. The ore is a mixture of minerals and rock (called gangue).
Global Hunter Corp. engages in the acquisition, exploration, and development of mineral properties in Canada and Chile. It primarily explores for gold, copper, and base and precious metals. Global Hunter Corp. (BOB.V) company was founded in 1988 and is headquartered in Vancouver, Canada.
Global Hunter Corp. (BOB.V) is also pleased to announce that it has retained the services of Vicarage Capital Limited of London, England to advise it on M&A and corporate finance issues. The key objective is to secure additional financial resources to advance its Corona de Cobre project through any of the following options: negotiating a strategic alliance with a company with significant financial resources; entering into a joint venture, or negotiating a possible merger. The Company has agreed to pay Vicarage a total of $150,000 CAD over the one-year term of the contract. Vicarage may also be entitled to certain success fees subject to TSX Venture Exchange approval.
For more information about Global Hunter Corp please visit http://www.globalhunter.ca
POWER 3 MEDICAL PROD (PWRM)
There are several types of breast cancer, but some of them are quite rare. In some cases a single breast tumor can have a combination of these types or have a mixture of invasive and in situ cancer.
Ductal carcinoma in situ; Ductal carcinoma in situ (DCIS; also known as intraductal carcinoma) is the most common type of non-invasive breast cancer. DCIS means that the cancer cells are inside the ducts but have not spread through the walls of the ducts into the surrounding breast tissue. About 1 in 5 new breast cancer cases will be DCIS. Nearly all women diagnosed at this early stage of breast cancer can be cured. A mammogram is often the best way to find DCIS early.
Lobular carcinoma in situ; although it is not a true cancer, lobular carcinoma in situ (LCIS; also called lobular neoplasia) is sometimes classified as a type of non-invasive breast cancer, which is why it is included here. It begins in the milk-producing glands but does not grow through the wall of the lobules.
Invasive (or infiltrating) ductal carcinoma; this is the most common type of breast cancer. Invasive (or infiltrating) ductal carcinoma (IDC) starts in a milk passage (duct) of the breast, breaks through the wall of the duct, and grows into the fatty tissue of the breast. At this point, it may be able to spread (metastasize) to other parts of the body through the lymphatic system and bloodstream. About 8 of 10 invasive breast cancers are infiltrating ductal carcinomas.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
Power 3 Medical Product the NuroPro Blood Test is diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease . Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.
Power3 Medical Products, Inc. (PWRM) announced that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroProÂ®, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.
For more information please visit official website of PWRM:http://www.power3medical.com
Brunswick Corporation (NYSE:BC) Chairman and Chief Executive Officer Dustan E. McCoy, along with Senior Vice President and Chief Financial Officer Peter B. Hamilton, will present at following event for the financial community during May. The presentation is as follows: Mr. McCoy will present at the Baird`s 2011 Growth Stock Conference in Chicago May 11 at 6:45 a.m. (EDT), which will be available by webcast. On May 12, Mr. McCoy will participate in the Longbow Research Consumer Conference in New York City. No webcast is available.
Brunswick Corporation provides recreation products worldwide. Its Marine Engine segment offers sterndrive propulsion systems, and inboard and outboard engines under the Mercury, Mercury MerCruiser, Mariner, Mercury Racing, Mercury SportJet, Mercury Jet Drive, MotorGuide, Axius, Zeus, and MerCruiser 360 brand names, as well as marine parts and accessories under the Quicksilver, Mercury Precision Parts, Mercury Propellers, Attwood, Land N Sea, Benrock, Kellogg Marine, Diversified Marine Products, Sea Choice, and MotorGuide brand names.
Broadridge Financial Solutions Inc. (NYSE:BR) announced that its Board of Directors has declared a quarterly cash dividend of $0.15 per share. The dividend is payable on July 1, 2011, to stockholders of record at the close of business on June 15, 2011.
Broadridge Financial Solutions, Inc. provides technology-based solutions to the financial services industry in the United States, Canada, and the United Kingdom.
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).